Archivel Farma works on the discovery and initial clinical development of novel pharmaceutical agents of biological nature.
RUTI®, poly-antigenic vaccine made of fragments from Mycobacterium tuberculosis, detoxified, and formulated with liposomes. The vaccine is in phase II of clinical development for the prevention of active tuberculosis in individuals with latent tuberculosis infection (therapeutic use). RUTI® is as well under evaluation for its use in the treatment of active tuberculosis and in other therapeutic areas.
- Prevention and treatment of tuberculosis with biological agents
- Diseases or pathological conditions that could benefit from immunomodulatory treatments